Long-term survival outcome for pre-capillary pulmonary hypertension at a Japanese single center

被引:6
作者
Sugiyama, Yoichi [1 ]
Tahara, Nobuhiro [1 ]
Bekki, Munehisa [1 ]
Tahara, Atsuko [1 ]
Honda, Akihiro [1 ]
Maeda-Ogata, Shoko [1 ]
Sun, Jiahui [1 ]
Igata, Sachiyo [1 ]
Fukumoto, Yoshihiro [1 ]
机构
[1] Kurume Univ, Sch Med, Dept Med, Div Cardiovasc Med, Kurume, Fukuoka, Japan
基金
日本学术振兴会;
关键词
pulmonary hypertension; pre-capillary pulmonary hypertension; pulmonary arterial hypertension; survival outcome; PAH-targeted drugs; ARTERIAL-HYPERTENSION; SYSTEMIC-SCLEROSIS; DOUBLE-BLIND; DIAGNOSIS; THERAPY;
D O I
10.1139/cjpp-2019-0663
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In recent years, several treatment options for patients with pre-capillary pulmonary hypertension (PH) have improved the short-term prognosis. However, the long-term survival for pre-capillary PH has not been well investigated. This study sought to investigate the long-term survival for pre-capillary PH in Kurume University Hospital. A total of 144 patients with pre-capillary PH (110 women, mean age 55.1 +/- 17.9 years) were enrolled. The maximal duration of followup was 15 years with a mean followup of 5.77 years. The 15 year survival was 59.1% for pre-capillary PH, 68.5% for pulmonary arterial hypertension (PAH), and 44.3% for chronic thromboembolic PH. The 5 year survival was 50.9% for PH due to lung disease (PH-LD), indicating the worst in the pre-capillary PH subgroups. The survival for portopulmonary hypertension was the lowest among PAH groups, and PAH associated with connective tissue disease and congenital heart disease decreased 10 years after diagnosis. A 6 min walk distance and elevated brain natriuretic peptide were significantly associated with survival outcome in pre-capillary PH patients and diastolic pulmonary arterial pressure was related to survival for PH-LD. The survivals were different among pre-capillary PH groups in our hospital. Above all, the long-term survival was better than in previous reports.
引用
收藏
页码:644 / 652
页数:9
相关论文
共 24 条
[1]  
Barst R.J., 1966, NEW ENGL J MED, V334, P296
[2]   Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL Identifying Systemic Sclerosis as a Unique Phenotype [J].
Chung, Lorinda ;
Liu, Juliana ;
Parsons, Lori ;
Hassoun, Paul M. ;
McGoon, Michael ;
Badesch, David B. ;
Miller, Dave P. ;
Nicolls, Mark R. ;
Zamanian, Roham T. .
CHEST, 2010, 138 (06) :1383-1394
[3]   Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity [J].
Cottin, V ;
Nunes, H ;
Brillet, PY ;
Delaval, P ;
Devouassoux, G ;
Tillie-Leblond, I ;
Israel-Biet, D ;
Court-Fortune, I ;
Valeyre, D ;
Cordier, JF .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (04) :586-593
[4]   ATS statement: Guidelines for the six-minute walk test [J].
Crapo, RO ;
Casaburi, R ;
Coates, AL ;
Enright, PL ;
MacIntyre, NR ;
McKay, RT ;
Johnson, D ;
Wanger, JS ;
Zeballos, RJ ;
Bittner, V ;
Mottram, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) :111-117
[5]   Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):: a double-blind, randomised controlled trial [J].
Galie, N. ;
Rubin, L. J. ;
Hoeper, M. M. ;
Jansa, P. ;
Al-Hiti, H. ;
Meyer, G. M. B. ;
Chiossi, E. ;
Kusic-Pajic, A. ;
Simonneau, G. .
LANCET, 2008, 371 (9630) :2093-2100
[6]   Sildenafil citrate therapy for pulmonary arterial hypertension [J].
Galiè, N ;
Ghofrani, HA ;
Torbicki, A ;
Barst, RJ ;
Rubin, LJ ;
Badesch, D ;
Fleming, T ;
Parpia, T ;
Burgess, G ;
Branzi, A ;
Grimminger, F ;
Kurzyna, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157
[7]   Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 [J].
Galie, Nazzareno ;
Olschewski, Horst ;
Oudiz, Ronald J. ;
Torres, Fernando ;
Frost, Adaani ;
Ghofrani, Hossein A. ;
Badesch, David B. ;
McGoon, Michael D. ;
McLaughlin, Vallerie V. ;
Roecker, Ellen B. ;
Gerber, Michael J. ;
Dufton, Christopher ;
Wiens, Brian L. ;
Rubin, Lewis J. .
CIRCULATION, 2008, 117 (23) :3010-3019
[8]   2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) [J].
Galie, Nazzareno ;
Humbert, Marc ;
Vachiery, Jean-Luc ;
Gibbs, Simon ;
Lang, Irene ;
Torbicki, Adam ;
Simonneau, Gerald ;
Peacock, Andrew ;
Noordegraaf, Anton Vonk ;
Beghetti, Maurice ;
Ghofrani, Ardeschir ;
Gomez Sanchez, Miguel Angel ;
Hansmann, Georg ;
Klepetko, Walter ;
Lancellotti, Patrizio ;
Matucci, Marco ;
McDonagh, Theresa ;
Pierard, Luc A. ;
Trindade, Pedro T. ;
Zompatori, Maurizio ;
Hoeper, Marius .
EUROPEAN HEART JOURNAL, 2016, 37 (01) :67-+
[9]   Tadalafil Therapy for Pulmonary Arterial Hypertension [J].
Galie, Nazzareno ;
Brundage, Bruce H. ;
Ghofrani, Hossein A. ;
Oudiz, Ronald J. ;
Simonneau, Gerald ;
Safdar, Zeenat ;
Shapiro, Shelley ;
White, R. James ;
Chan, Melanie ;
Beardsworth, Anthony ;
Frumkin, Lyn ;
Barst, Robyn J. .
CIRCULATION, 2009, 119 (22) :2894-U65
[10]   Riociguat for the Treatment of Pulmonary Arterial Hypertension [J].
Ghofrani, Hossein-Ardeschir ;
Galie, Nazzareno ;
Grimminger, Friedrich ;
Gruenig, Ekkehard ;
Humbert, Marc ;
Jing, Zhi-Cheng ;
Keogh, Anne M. ;
Langleben, David ;
Kilama, Michael Ochan ;
Fritsch, Arno ;
Neuser, Dieter ;
Rubin, Lewis J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (04) :330-340